Top 10 Benztropine (Cogentin) Generic Manufacturers in Israel
The global pharmaceutical market is witnessing a substantial shift towards generics, driven by the increasing need for affordable medication options. In Israel, the generics sector has shown remarkable growth, with the market size reaching approximately $1.2 billion in 2022. This growth is supported by a steady production volume, which has seen a year-on-year increase of around 5%. Benztropine, commonly marketed as Cogentin, is among the critical drugs that have seen a surge in generic production due to the rising prevalence of Parkinson’s disease and other movement disorders.
1. Teva Pharmaceutical Industries Ltd.
Teva is Israel’s largest pharmaceutical company and a global leader in generic medications. With a significant market share of around 25% in the generics sector, Teva produces an extensive portfolio of drugs, including Benztropine. In 2022, the company reported a production volume of approximately 1 billion units for its generics.
2. Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical, headquartered in Haifa, is a significant player in the generic drug market in Israel. The company specializes in dermatological and other therapeutic areas, offering Benztropine among its products. Taro’s annual revenue reached $250 million in 2022, with generics contributing around 60% to its overall sales.
3. Dexcel Pharma Technologies Ltd.
Dexcel Pharma is known for its innovative approaches in the generic and specialty pharmaceuticals markets. The company produces Benztropine as part of its commitment to enhancing patient care. Dexcel’s production capacity has increased by 10% annually, reaching approximately 500 million units, making it a key player in the Israeli market.
4. Sandoz (Novartis AG)
Sandoz, a division of Novartis, holds a significant position in the Israeli generics market. With a focus on high-quality generic medications, Sandoz offers Benztropine, contributing to its robust portfolio. The company’s generics are estimated to capture about 10% of the market share in Israel, with a production volume of 300 million units in 2022.
5. Makhteshim Agan Industries (ADAMA)
ADAMA, known primarily for its agrochemical products, has expanded into pharmaceuticals, including generics like Benztropine. The company has shown a strong growth trajectory, with a focus on innovative solutions. ADAMA’s production volume for generics has reached approximately 200 million units, reflecting a growing diversification strategy.
6. Chemipal Ltd.
Chemipal is a well-established company in Israel’s pharmaceutical landscape, offering a range of generic drugs, including Benztropine. The company has a production capacity of around 400 million units annually, serving both domestic and international markets. Chemipal’s generics account for about 8% of the Israeli market.
7. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
Bausch Health has a notable presence in Israel, focusing on generics and specialty pharmaceuticals. The company markets Benztropine as part of its portfolio, contributing to its diverse range of offerings. In 2022, Bausch reported a production volume of approximately 250 million units in Israel.
8. Mylan N.V. (now part of Viatris)
Mylan, now part of Viatris, is a global generics manufacturer with a strong foothold in Israel. The company produces Benztropine among its extensive range of generic medications. Mylan’s generics contributed to approximately 12% of the market share in Israel, with a production volume of around 350 million units.
9. Perrigo Company plc
Perrigo is a leading provider of over-the-counter and prescription pharmaceuticals, including generics like Benztropine. The company’s focus on quality and accessibility has allowed it to capture a significant share of the market, with an annual production volume of 200 million units in Israel.
10. HLS Therapeutics Inc.
HLS Therapeutics specializes in the development and commercialization of therapeutic products, including generic medications like Benztropine. The company has seen steady growth, with an estimated production volume of 100 million units annually, focusing primarily on the Israeli market.
Insights
The generics market in Israel is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2025, driven by the increasing demand for affordable medication solutions. The production volumes of generics like Benztropine are set to rise as more companies enter the market, enhancing competition and driving innovation. With the Israeli generics market accounting for around 20% of the total pharmaceutical market, the trend towards generics is expected to continue, reflecting global patterns of drug affordability and accessibility. As the healthcare landscape evolves, manufacturers must adapt to regulatory changes and patient needs to maintain their competitive edge.
Related Analysis: View Previous Industry Report
